These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38722400)

  • 1. Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study.
    Martínez-Laguna D; Carbonell Abella C; Bastida JC; González M; Micó-Pérez RM; Vargas F; Díaz Torres E; Canals L;
    Arch Osteoporos; 2024 May; 19(1):35. PubMed ID: 38722400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study.
    Martínez-Laguna D; Carbonell C; Bastida JC; González M; Micó-Pérez RM; Vargas F; Balcells-Oliver M; Canals L;
    Arch Osteoporos; 2022 Jul; 17(1):93. PubMed ID: 35836031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
    Fujiwara S; Miyauchi A; Hamaya E; Nicholls RJ; Weston A; Baidya S; Pinto L; Barron R; Takada J
    Arch Osteoporos; 2018 Mar; 13(1):34. PubMed ID: 29564555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary and Secondary Prevention of Hip Fragility Fracture in Teruel Health Sector, Aragon, Spain].
    Gómez Navarro R; González García P; Martín Hernández C; Castro Sauras Á; Valdearcos Enguídanos S
    Rev Esp Salud Publica; 2017 Jan; 91():. PubMed ID: 28025971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary prevention of osteoporosis following fragility fractures of the distal radius in a large health maintenance organization.
    Benzvi L; Gershon A; Lavi I; Wollstein R
    Arch Osteoporos; 2016; 11():20. PubMed ID: 27142832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study of osteoporosis management after a fragility fracture in primary care.
    Bell A; Kendler DL; Khan AA; Shapiro C M M; Morisset A; Leung JP; Reiner M; Colgan SM; Slatkovska L; Packalen M
    Arch Osteoporos; 2022 May; 17(1):75. PubMed ID: 35513573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.
    Shah A; Prieto-Alhambra D; Hawley S; Delmestri A; Lippett J; Cooper C; Judge A; Javaid MK;
    Osteoporos Int; 2017 Jan; 28(1):169-178. PubMed ID: 27812809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].
    Naranjo A; Ojeda-Bruno S; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Rodríguez-Lozano C
    Med Clin (Barc); 2011 Mar; 136(7):290-2. PubMed ID: 21185575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
    Antonelli M; Einstadter D; Magrey M
    J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
    Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
    Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.